对耐火性类风湿性关节炎的双特异性T细胞诱导疗法
Laura Bucci1,2, Melanie Hagen1,2, Tobias Rothe1,2
1Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany.
Nature medicine
|April 26, 2024
概括
双特异性T细胞参与剂 (BiTEs) 通过耗尽B细胞来治疗类风湿性关节炎 (RA) 是有前途的. 这种方法为RA和其他自身免疫性疾病提供了潜在的新疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 瘤免疫学 瘤免疫学
背景情况:
- 双特异性T细胞参与剂 (BiTEs) 有效地向B细胞,特别是在血液性恶性瘤中.
- 类风湿性关节炎 (RA) 是一种慢性自身免疫性疾病,其特点是B细胞的参与和对传统疗法的抵抗.
研究的目的:
- 为了研究CD19xCD3BiTE,布利纳图马布的安全性和有效性,在患有多药耐药性类风湿性关节炎的患者中.
- 探索布利纳图马布对B细胞群和RA疾病活性的影响.
主要方法:
- 六名耐火性RA患者接受了低剂量的blinatumomab在同情使用下.
- 通过临床评估,成像 (超声波,FAPI-PET-CT),自身抗体水平和B细胞高维流细胞计分析来评估治疗结果.
主要成果:
- 布利纳莫马布治疗导致B细胞枯竭和T细胞减少,证实了吸引功能.
- 所有患者都经历了RA疾病活性的快速减少,突炎的改善和自身抗体的减少.
- 治疗是安全的,副作用可控,没有临床显著的细胞因子释放综合征.
- 流细胞计揭示了一种免疫重置,其特征是激活的记忆B细胞的枯竭和与天真B细胞的重新填充.
结论:
- 低剂量的布利纳马布是一种可行的,潜在的有效治疗类风湿性关节炎的方法.
- 双TEs可能为B细胞介导的自身免疫性疾病提供一种新的治疗策略,需要进一步研究.
相关概念视频
Tumor Immunotherapy
520
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
520
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
134
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
134
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)

